Evidence map›Paper›PMID 40759858›Full record

ArticleImmunologic research2025

SOCS1 improves abnormal IgA galactosylation in IgA nephropathy by regulating the TLR9/MyD88 pathway.

Yanru Huang, Qinghai Wang, Chunqin Lin, Bingbing Qiu, Shulian Chen, Jianxin Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanru HuangDepartment of Pediatrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Qinghai WangDepartment of Pediatrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Chunqin LinDepartment of Pediatrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Bingbing QiuDepartment of Pediatrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Shulian ChenDepartment of Pediatrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Jianxin WangDepartment of Pediatrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, Fujian Province, China. qzduan2018@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormal galactosylation of IgA is a core factor in the development of IgA nephropathy (IgAN). Suppressor of cytokine signaling 1 (SOCS1) expression negatively correlates with IgA1 secretion in IgAN patients and that TLR9/MyD88 promotes aberrantly glycosylated IgA formation. Therefore, the present study exposed whether SOCS1 is involved in aberrant galactosylation of IgA in IgAN by regulating the TLR9/MyD88 signaling pathway through in vivo and in vitro experiments. Differential expression of SOSC1 in IgAN patients and non-IgAN patients was analyzed using bioinformatics analysis and immunofluorescence. The IgAN mouse model and the IgA1-secreting DAKIKI cell model were used to validate the effect of SOCS1 on aberrant IgA galactosylation in IgAN. In addition, qRT-PCR, western blot, and immunohistochemistry experiments were performed to reveal the regulation of the TLR9/MyD88 pathway by SOCS1 in IgAN. The expression of SOCS1 was suppressed in renal tissues and peripheral blood mononuclear cells (PBMC) of IgAN patients, consistent with the results of dataset GSE35487. The expression of C1GALT1 in PBMC from IgAN patients was decreased and positively correlated with SOCS1 expression, while the expressions of TLR9 and MyD88 were increased and negatively correlated with SOCS1 expression. In vitro, SOCS1 overexpression inhibited the secretion of IgA1 and galactose-deficient IgA1 (Gd-IgA1) in DAKIKI cells, as well as the expression of TLR9. Knockdown of SOCS1 had the opposite effect. As a negative regulator of TLR9, SOCS1 inhibited the expression of TLR9, thereby preventing aberrant IgA galactosylation. MyD88 knockdown restored the CpG-ODN (TLR9 ligand)-induced overproduction of IgA1 and Gd-IgA1, and the reduction of C1GALT1. In vivo experiments demonstrated that SOCS1 significantly inhibited the production of aberrant glycosylated IgA IgG-IgA immune complexes and IL-6 in mice, reduced glomerular IgA, IgG, and C3 deposition and tethered cell proliferation, and alleviated renal injury. Decreased expression of SOCS1 contributes to IgAN pathogenesis by promoting aberrant IgA galactosylation via activating TLR9/MyD88 pathway. Our study may provide a prospective treatment target for IgAN.

Indexed as

Glomerulonephritis, IGAImmunoglobulin AMyeloid Differentiation Factor 88Suppressor of Cytokine Signaling 1 ProteinToll-Like Receptor 9AdultAnimalsCell LineDisease Models, AnimalFemaleGalactosyltransferasesGlycosylationHumansMaleMiceSignal TransductionC1GALT1 protein, humanGalactosyltransferasesImmunoglobulin AMYD88 protein, humanMyeloid Differentiation Factor 88SOCS1 protein, humanSocs1 protein, mouseSuppressor of Cytokine Signaling 1 ProteinTLR9 protein, humanToll-Like Receptor 9GalactosylationIgA nephropathyMyD88SOCS1TLR9

Identifiers

PMID40759858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.